Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Total Valuation
Sutro Biopharma has a market cap or net worth of $428.43M. The enterprise value is $396.83M.
Market Cap$428.43M
Enterprise Value$396.83M
Share Statistics
Sutro Biopharma has 16,567,238 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,567,238
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sutro Biopharma’s return on equity (ROE) is 1.44 and return on invested capital (ROIC) is -98.52%.
Return on Equity (ROE)1.44
Return on Assets (ROA)-1.10
Return on Invested Capital (ROIC)-98.52%
Return on Capital Employed (ROCE)-1.06
Revenue Per Employee380.98K
Profits Per Employee-710.36K
Employee Count269
Asset Turnover0.59
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sutro Biopharma is ―. Sutro Biopharma’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.96
PB Ratio-0.74
Price to Fair Value-0.74
Price to FCF-0.55
Price to Operating Cash Flow-1.25
PEG Ratio0.02
Income Statement
In the last 12 months, Sutro Biopharma had revenue of 102.48M and earned -191.09M in profits. Earnings per share was -22.49.
Revenue102.48M
Gross Profit95.16M
Operating Income-104.95M
Pretax Income-191.18M
Net Income-191.09M
EBITDA-97.63M
Earnings Per Share (EPS)-22.49
Cash Flow
In the last 12 months, operating cash flow was -177.23M and capital expenditures -1.70M, giving a free cash flow of -178.93M billion.
Operating Cash Flow-177.23M
Free Cash Flow-178.93M
Free Cash Flow per Share-10.80
Dividends & Yields
Sutro Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.42
52-Week Price Change333.24%
50-Day Moving Average20.80
200-Day Moving Average12.31
Relative Strength Index (RSI)61.54
Average Volume (3m)987.85K
Important Dates
Sutro Biopharma upcoming earnings date is May 13, 2026, TBA (Confirmed).
Last Earnings DateMar 23, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Sutro Biopharma as a current ratio of 2.01, with Debt / Equity ratio of -177.58%
Current Ratio2.01
Quick Ratio2.01
Debt to Market Cap0.16
Net Debt to EBITDA0.43
Interest Coverage Ratio-2.75
Taxes
In the past 12 months, Sutro Biopharma has paid -93.00K in taxes.
Income Tax-93.00K
Effective Tax Rate<0.01
Enterprise Valuation
Sutro Biopharma EV to EBITDA ratio is -0.57, with an EV/FCF ratio of -0.31.
EV to Sales0.55
EV to EBITDA-0.57
EV to Free Cash Flow-0.31
EV to Operating Cash Flow-0.32
Balance Sheet
Sutro Biopharma has $141.43M in cash and marketable securities with $235.21M in debt, giving a net cash position of -$93.78M billion.
Cash & Marketable Securities$141.43M
Total Debt$235.21M
Net Cash-$93.78M
Net Cash Per Share-$5.66
Tangible Book Value Per Share-$15.59
Margins
Gross margin is 98.42%, with operating margin of -102.41%, and net profit margin of -186.45%.
Gross Margin98.42%
Operating Margin-102.41%
Pretax Margin-186.55%
Net Profit Margin-186.45%
EBITDA Margin-95.26%
EBIT Margin-102.41%
Analyst Forecast
The average price target for Sutro Biopharma is $26.86, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$26.86
Price Target Upside3.87% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast-34.36%
EPS Growth Forecast-59.98%